Approved Conversion of 7,35,000 warrants into Equity Shares
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shelter Pharma Ltd's Board approved the conversion of 7,35,000 warrants into an equal number of equity shares of face value ₹10 each, at an issue price of ₹42.25 per share (including a premium of ₹32.25). The conversion was exercised by two promoter group members — Shakil Nisarahmed Sabugar (4,50,000 shares) and Managing Director Mustaqim Nisarahmed Sabugar (2,85,000 shares) — who paid the remaining 75% balance of ₹31.6875 per warrant, aggregating to ₹2.33 crore. This was part of the original 88,08,000 warrants allotted on a preferential basis in August 2025. Following this conversion, the company's paid-up equity capital rose from ₹15.60 crore (1,55,97,792 shares) to ₹16.33 crore (1,63,32,792 shares), a dilution of roughly 4.7%. The new shares will rank equally with existing equity shares, and listing approval will be sought from BSE.
The conversion is entirely from the promoter group, reflecting insider confidence and commitment of additional capital into the company. Existing shareholders will see a minor dilution of about 4.7%, but since it is promoter-led, it is generally viewed as a positive signal rather than a supply overhang.